Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

TAT 2018 Press Release: "Fighting my Cancer as Much as Possible": Why Many Patients Join Phase 1 Clinical Trials

05 Mar 2018
Translational research;  Personalised medicine;  Anticancer agents & Biologic therapy

LUGANO, Switzerland – ”Fighting my cancer as much as possible” is why many patients participate in early stage clinical trials, according to research presented at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris, France.

Markus Joerger

Dr Markus Joerger

“The importance of early stage trials is increasing because of the pressing need for new drugs,” said Dr Markus Joerger, Attending Medical Oncologist and responsible of the phase 1 unit at St Gallen Cancer Centre, Switzerland, member of the ESMO Press and Media Committee. This has been accompanied by rising interest from patients in participating in such trials due to the introduction of alternatives to chemotherapy and larger trials which benefit more patients.

Joerger said: “The public is aware that cancer treatment is not just chemotherapy, which is often accompanied by substantial side-effects; we now also have targeted drugs and immunotherapy. In addition, we have a deeper understanding of tumour biology and can better select patients for trials, leading to higher response rates and increased clinical benefit. Early stage trials include more patients than before, so there is the potential for greater numbers of patients to benefit.”

Dr Benjamin Verret of the Drug Development Unit (DITEP), Institut Gustave Roussy, Villejuif, France, author of a study analysing the answers to a self-administered questionnaire assessing patient preferences for participation in phase 1 clinical trials, (1) said: “Ten years ago, phase 1 clinical trials were maybe the only option for patients with a cancer at an advanced stage that would not respond to standard treatment. Today this is no longer the case. Participants in early stage trials gain access to treatment alternatives such as targeted therapy and immune checkpoint inhibitors.”

Verret’s research found that “fighting my cancer as much as possible” was one of the top two reasons why patients choose to participate in a phase 1 clinical trial. He said: “In our study, only one in six patients said that clinical trial participation was their only option. More than two-thirds said their reason for taking part was ‘having access to the best cancer treatment’. These findings suggest an improvement in the public’s opinion of clinical trials. Interestingly, a survey we conducted among oncologists referring patients to our phase 1 trial unit also indicates more public support for early stage trials.”

Commenting on the study, Joerger said: “This study suggests that the attractiveness of early stage clinical trials has improved. The centre where I work, for example has also had an increase in referrals to these trials over the last ten years. Cancer therapy is becoming more personalised, and patients mayhave longer responses and less toxicity than with chemotherapy.”

Selection of patients is crucial to achieving the aims of phase 1 trials, which are to determine the correct dose and safety of a new drug. Another study presented at the TAT International Congress 2018 provided external validation of a score which predicts overall survival of patients in phase 1 immuno-oncology trials and can be used to select participants. (2)

Study author Dr Lucia Ceniceros of the Clínica Universidad de Navarra, Pamplona, Spain, said: “The score is particularly useful for determining the most appropriate patients to receive treatment in a phase 1 immuno-oncology trial. Selecting the correct patients should reduce toxicities and improve survival.”

Joerger added: “The score can improve understanding about the impact of immunotherapy generally. In future what we really need is predictive markers for specific immunotherapy drugs. Over the next five years we will have many more immunotherapy drugs and specific predictors should be developed for each therapy.”


Dr Ahmad Awada

Dr Ahmad Awada, Head of Medical Oncology at the Jules Bordet Institute in Brussels, Belgium, expert in new drug development and Coordinator of the ESMO Faculty of Principles of clinical trials and systemic therapy, commented: “The proper selection of patients is crucial for a correct evaluation of a new agent in the phase 1 setting as the evaluation of the tolerance and the efficacy for the majority of patients is analysed at a later stage.”

Awada also emphasised the importance of patient’s informed consent when they are offered participation in early and/or later phase clinical trials: “New electronic tools are currently being developed in order to facilitate a patient’s understanding and participation in clinical trials and to refine their expectations.”

Joerger concluded: “Patients with cancer are becoming more and more interested in taking part in phase 1 clinical trials and research presented at the TAT International Congress 2018 confirms that this is not because these trials are their only option. More research is needed to improve patient selection for phase 1 trials so that even more patients with cancer can benefit.”

Notes to Editors

Please make sure to use the official name of the meeting in your reports: TAT International Congress 2018

Official hashtag for TAT International Congress 2018: #TAT2018

  1. Abstract 141P ‘Self-questionnaire to assess patient’s preferences for participation in phase I clinical trials‘ will be presented by Benjamin Verret during the Poster display session on Monday, 5 March, 17:10 to 18:00 (CET) in Room Scene AB. Annals of Oncology, Volume 29, 2018 Supplement 3. doi:10.1093/annonc/mdy046
  2. Abstract 117P ‘External Validation of the Gustave Roussy Immune Score (GRIm score) in an unselected cohort of patients treated at the Clinica Universidad de Navarra‘ will be presented by Lucia Ceniceros during a Poster display session on Monday, 5 March, 17:10 to 18:00 (CET) in Room Scene AB. Annals of Oncology, Volume 29, 2018 Supplement 3. doi:10.1093/annonc/mdy046

This press release contains information provided by the authors of the highlighted abstracts and reflects the content of those abstracts. It does not necessarily reflect the views or opinions of ESMO who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct.

About the European Society for Medical Oncology (ESMO)

ESMO is the leading professional organisation for medical oncology. With 18,000 members representing oncology professionals from over 150 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.

Last update: 05 Mar 2018

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.